Autologous Stem Cell Treatment for Chronic Lung Disease Study
| Status: | Completed |
|---|---|
| Conditions: | Lung Cancer, Chronic Obstructive Pulmonary Disease, Pulmonary, Pulmonary |
| Therapuetic Areas: | Oncology, Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 16 - Any |
| Updated: | 10/17/2018 |
| Start Date: | April 1, 2016 |
| End Date: | June 9, 2017 |
The purpose of the Lung Institute is to collect and isolate a patient's own cells and
platelet rich plasma (PRP) and deliver the product back to the patient the same day. Lung
Institute's treatment is limited to self-funded patients with chronic lung disease- chronic
obstructive pulmonary disease (COPD) and restrictive lung diseases such as pulmonary fibrosis
(PF) and interstitial lung disease (ILD). The patient's cells and platelet rich plasma are
harvested through venous or bone marrow collection techniques.
The hypothesized outcomes of therapy are safety and minimization of adverse events, a
perceived improvement in the patient's lung condition (to be determined by their perceived
quality of life), an improvement in the FEV1 among COPD patients, the ability to reduce
supplemental oxygen use, the ability to function well without the use of rescue inhalers,
reduction of secondary pulmonary infections, reduction in emergency room visits and
exacerbations related to their disease.
platelet rich plasma (PRP) and deliver the product back to the patient the same day. Lung
Institute's treatment is limited to self-funded patients with chronic lung disease- chronic
obstructive pulmonary disease (COPD) and restrictive lung diseases such as pulmonary fibrosis
(PF) and interstitial lung disease (ILD). The patient's cells and platelet rich plasma are
harvested through venous or bone marrow collection techniques.
The hypothesized outcomes of therapy are safety and minimization of adverse events, a
perceived improvement in the patient's lung condition (to be determined by their perceived
quality of life), an improvement in the FEV1 among COPD patients, the ability to reduce
supplemental oxygen use, the ability to function well without the use of rescue inhalers,
reduction of secondary pulmonary infections, reduction in emergency room visits and
exacerbations related to their disease.
Through the collection of outcomes data, Lung Institute aims to explore and describe the
safety and efficacy of autologous stem cell treatment for chronic lung disease with
dissemination to the public and to the medical community for the advancement of regenerative
medicine. The study aims to confirm the safety of autologous cell therapy, explore the effect
of autologous cell therapy treatment on pulmonary function over time, and to describe the
anecdotal quality of life changes of patients following treatment using quantitative and
qualitative measures.
safety and efficacy of autologous stem cell treatment for chronic lung disease with
dissemination to the public and to the medical community for the advancement of regenerative
medicine. The study aims to confirm the safety of autologous cell therapy, explore the effect
of autologous cell therapy treatment on pulmonary function over time, and to describe the
anecdotal quality of life changes of patients following treatment using quantitative and
qualitative measures.
Inclusion Criteria:
- Patients are included in treatment by self-referral and after consultation with a
designated patient coordinator who determines initial eligibility, and then by the
clinic nurse practitioner or physician of Lung Institute who determines final
eligibility for inclusion. All eligible treated patients are eligible for the study.
Exclusion Criteria:
- Patients who are unable to provide informed consent, pregnant patients, prisoners,
non-English speakers, patients with a history of cancer within the past 5 years,
patients with active tuberculosis or pneumonia. In addition, patients on prescribed
blood thinners, with a history of breast or prostate cancer of any time frame or with
a history of osteoporosis are excluded from the bone marrow harvest option.
We found this trial at
1
site
Click here to add this to my saved trials
